20Mar 2025
Switching to iGlarLixi Improves Glycemic Control in Type 2 Diabetes

Switching to iGlarLixi Improves Glycemic Control in Type 2 Diabetes

iGlarLixi improves glycemic control without weight gain or increased hypoglycemia over 24 weeks. 162 participants switched from premixed insulin (89.5% from twice-daily). HbA1c dropped by 1.2%, with 37.6% reaching <7%. Body weight decreased by 1.0 kg, and fasting/post-prandial glucose improved significantly. 38.3% of participants experienced confirmed symptomatic hypoglycemia. This treatment effectively manages glucose with minimal adverse effects.

  • #endo-diabetology

Like

Save

Share